Low Insulin Costs on the Horizon?
Diabetes, one of the most prevalent healthcare issues faced by American seniors, often carries with it pretty steep costs related to the insulin drugs needed to combat the disease. Of course, lowering the costs of prescription medications is in the spotlight in this election year, but now some action is actually being taken to at least provide relief to diabetics who rely on insulin. The Trump Administration has put forth a new pilot program to cap insulin costs at $35 per month, and many drug manufacturers are supportive of the idea. This New York Times article by Katie Thomas explains how the pilot program would work and how the major drug manufacturers have, mostly positively, reacted to it. Click here to read more.